```
=> FIL PNTTEXT
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.15       0.15

FILE 'EUROPATFULL' ENTERED AT 14:34:41 ON 20 JUN 2001
COPYRIGHT (c) 2001 WILA Verlag Muenchen (WILA)

FILE 'PCTFULL' ENTERED AT 14:34:41 ON 20 JUN 2001
COPYRIGHT (C) 2001 MicroPatent

FILE 'USPATFULL' ENTERED AT 14:34:41 ON 20 JUN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (amyloid(2w)protein) or app or ?amyloid(2a)protein or alzheimer?
L1       29988 (AMYLOID(2W) PROTEIN) OR APP OR ?AMYLOID(2A) PROTEIN OR
ALZHEIME
               R?

=> s ((hmg-coa)(2a)(reductase))(3a)inhibit? or ?statin#
TRUNCATION COMBINATION NOT VALID '?STATIN#'
TRUNCATION COMBINATION NOT VALID '?STATIN#'
TRUNCATION COMBINATION NOT VALID '?STATIN#'
Simultaneous left and right truncation is not possible for this
combination of truncation symbols.  For more information about
truncation in the current file, enter "HELP TRUNCATION".

=> s ((hmg-coa)(2a)(reductase))(3a)(inhibit?) or ?statin#
TRUNCATION COMBINATION NOT VALID '?STATIN#'
TRUNCATION COMBINATION NOT VALID '?STATIN#'
TRUNCATION COMBINATION NOT VALID '?STATIN#'
Simultaneous left and right truncation is not possible for this
combination of truncation symbols.  For more information about
truncation in the current file, enter "HELP TRUNCATION".

=> s ((hmg-coa)(2a)(reductase))(3a)(inhibit?) or ?statin
   2 FILES SEARCHED...
L2       20248 ((HMG-COA)(2A)(REDUCTASE))(3A)(INHIBIT?) OR ?STATIN

=> s l1(l)l2
L3        2819 L1(L) L2

=> d hit

L3     ANSWER 1 OF 2819  EUROPATFULL  COPYRIGHT  2001 WILA
DETDEN Two forms of COX are now known, a constitutive isoform (COX-1) and an
       inducible isoform (COX-2) of which expression is upregulated at sites
of
       inflammation (Vane, J. R.; Mitchell, J. A.; Appleton, I.; Tomlinson,
A.;
       Bishop-Bailey, D.; Croxtoll, J.;Willoughby, D. A. Proc. Nail. Acad.
Sci.
       USA, 1994, 91, 2046). COX-1 is thought to play a physiological role and
       to be responsible for gastrointestinal and renal protection. On the
       other hand, COX-2 appears to play a pathological role and is believed
to
       be the predominant isoform present in inflammation conditions. A
       pathological role for prostaglandins has been implicated in a number of
```

human disease states including rheumatoid arthritis and osteoarthritis, pyrexia, asthma, bone resorption, cardiovascular diseases, dysmenorrhea, premature labour, nephritis, nephrosis, atherosclerosis, hypotension, shock, pain, cancer, and **Alzheimer** disease. It is believed that compounds that would selectively inhibit the biosynthesis of prostaglandins by intervention of activity of the enzyme COX-2 on arachidonic acid would provide alternate therapy to the use of conventional NSAIDs or corticosteriods in that such compounds would exert anti-inflammatory effects without the adverse side effects associated with COX-1 inhibition.

The compounds of the present invention may also be used in combination with anticancer agents such as **endostatin** and **angiostatin** or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, and antimetabolites such as methotrexate.

```
=>  d his

     (FILE 'HOME' ENTERED AT 14:43:47 ON 20 JUN 2001)

     FILE 'EUROPATFULL, PCTFULL, USPATFULL' ENTERED AT 14:44:17 ON 20 JUN 2001

     FILE 'USPATFULL' ENTERED AT 14:44:39 ON 20 JUN 2001
L1         12546 S (AMYLOID(2W)PROTEIN) OR APP OR ?AMYLOID(2A)PROTEIN OR
ALZHEIM
L2          9352 S ((HMG-COA)(2A)(REDUCTASE))(3A)INHIBIT? OR ?STATIN
L3           939 S L1(L)L2
L4           415 S L3 NOT PY>=1999
L5           887 S LOVASTATIN
L6            33 S L1(L)L5
L7             6 S L6 NOT PY>=1999
```

L1 ANSWER 3 OF 7 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 2001032161 PCTFULL EW 200119 ED 20010528
TITLE (ENGLISH): METHOD OF TREATING AMYLOID β PRECURSOR DISORDERS
TITLE (FRENCH): METHODE DE TRAITEMENT DE TROUBLES LIES AU PRECURSEUR BETA-AMYLOIDE
INVENTOR(S): **FRIEDHOFF, Lawrence**; BUXBAUM, Joseph
PATENT ASSIGNEE(S): ANDRX CORPORATION
AGENT: HERBERT, Toni-Junell
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001032161	A2	20010510

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US41841	20001103
PRIORITY (ORIGINAL):	US 1999-60/163608	19991104
	US 2000-60/219435	20000720
	US 2000-60/223987	20000809

L1 ANSWER 4 OF 7 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998055106 PCTFULL
TITLE (ENGLISH): METHOD FOR PREPARING PHARMACEUTICAL FORMULATION
TITLE (FRENCH): PROCEDE DE PREPARATION D'UNE FORMULATION PHARMACEUTIQUE
INVENTOR(S): ASAI, Yasuyuki; ONAI, Katsumi; IWAMOTO, Kiyoshi;

```
=> e friedhoff lawrence/in
E1            4      FRIEDHOFF ARNOLD J/IN
E2            1      FRIEDHOFF CARL B/IN
E3            2 --> FRIEDHOFF LAWRENCE/IN
E4            3      FRIEDHOFF LAWRENCE T/IN
E5            1      FRIEDHOFF PETER/IN
E6            1      FRIEDHOFF ROBIN D/IN
E7            1      FRIEDHOFF ROLAND/IN
E8            1      FRIEDHOFPLATZ/IN
E9            1      FRIEDHOFSALLEE/IN
E10           1      FRIEDHOFSG/IN
E11           1      FRIEDHOFSGASSE/IN
E12          18      FRIEDHOFSTR/IN

=> s e3-e4
L1            7 ("FRIEDHOFF LAWRENCE"/IN OR "FRIEDHOFF LAWRENCE T"/IN)
```